R&D channel feed – Endpoints News

R&D channel feed

J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO

8 years ago

Looking for an early success in PhII Alzheimer’s study, Biogen and Eisai just racked up the latest setback

8 years ago

Another death mars AbbVie's latest batch of promising data for its star rheumatoid arthritis drug

8 years ago

GAO report tracks the growth of an $89B drug R&D sector as biopharma sales soared

8 years ago

With AveXis coming up in the rear view mirror, Biogen and Ionis go back to the drawing board on SMA

8 years ago

Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations

8 years ago

Is Roche's pRED finally ready to step out from behind Genentech for its closeup? Probably not

8 years ago

Shire hit by a setback as Hunter syndrome drug fails late-stage study

8 years ago

Severe job cuts at Teva incite massive worker strikes, shutting Israel down

8 years ago

Allergan and Gedeon Richter ready to knock on FDA's door after a positive PhIII for cariprazine in bipolar depression

8 years ago

One of Merck's pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

8 years ago

Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

8 years ago

Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring

8 years ago

NEA leads a big syndicate on $100M mega-round for Allakos

8 years ago

Daiichi ditches Nektar following cancer drug flop

8 years ago

Sanofi faces a make-or-break year, saying it’s ready to put a 3-prong R&D strategy to a pivotal test

8 years ago

Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt

8 years ago

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

8 years ago

Aduro buries another cancer vaccine after CRS-207 joins the lineup of clinical disasters

8 years ago

#ASH17: AbbVie, Roche boast stellar PhIII leukemia data for a “breakthrough” combo with blockbuster ambitions

8 years ago

GSK offers encouraging data on BCMA-targeting armed antibody, setting stage for a return to late-stage cancer studies

8 years ago

#ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky

8 years ago

First page Previous page 287 288 289290291 292 293 Next page Last page